PT-141 // LEGAL READING LIST
Q&A // RESEARCH QUESTIONS ANSWERED

Frequently Asked Questions: PT-141 (Bremelanotide)

10 MIN READ UPDATED 2025-06

These questions are answered directly from the bremelanotide clinical literature. Every quantitative claim below cites a source in the references index. PT-141 is the primary subject throughout.

QUESTION BANK // 24 ITEMS

PT-141 Research Q&A

  • PT-141 (bremelanotide) is a synthetic analogue of alpha-MSH that acts as an agonist at MC3R and MC4R receptors in the central nervous system, activating neural pathways associated with sexual arousal and desire. In the RECONNECT Phase 3 trials, it produced statistically significant improvements in satisfying sexual events and sexual distress measures in premenopausal women with HSDD versus placebo. In Phase 2 male studies, it produced dose-dependent erectile responses.
  • PT-141 is a 7-amino-acid cyclic peptide (bremelanotide) derived from melanotan II, studied for its melanocortin receptor agonist activity and its effects on central nervous system pathways governing sexual arousal. Molecular weight 1025.2 Da, molecular formula C50H68N14O10. FDA-approved in 2019 under the trade name Vyleesi for HSDD in premenopausal women.
  • PT-141 activates MC3R and MC4R receptors in the hypothalamus, bypassing vascular pathways entirely. Unlike PDE-5 inhibitors, it acts centrally on dopaminergic pathways linked to sexual motivation rather than on genital blood flow. MC4R activation in the medial preoptic area (mPOA) enhances presynaptic dopamine release, shifting the excitatory-inhibitory balance in brain arousal circuits toward desire initiation.
  • Preclinical and clinical studies document: increased sexual desire scores in women with HSDD (Phase 3 RECONNECT trials); pro-erectile activity in rat, primate, and human models; selective increase in appetitive sexual behaviors in rats; improved FSFI scores and reduced distress in Phase 3 subjects; and altered brain processing of erotic stimuli consistent with reduced self-monitoring. Most human efficacy data comes from Phase 2/3 bremelanotide trials.
  • Clinical trial data indicates effects lasting approximately 6–12 hours in human subjects, with onset typically 30–60 minutes after subcutaneous administration. The 1.75 mg SC dose has a plasma half-life of approximately 2.5 hours; blood pressure effects resolved within 12 hours in ambulatory monitoring studies. Duration varies by dose and individual subject response.
  • Key variables in PT-141 research include route of administration (subcutaneous vs. intranasal), dose range (0.3–20 mg in trials), subject population (premenopausal women with HSDD; men with ED), and outcome measures (FSFI desire domain, IIEF, satisfying sexual events per month, FSDS-DAO distress scale). The Phase 2b dose-ranging study established the 1.75 mg SC dose and defined minimum clinically important differences for Phase 3.
  • In Phase 3 trials, subjects reported onset of effect approximately 30–60 minutes after subcutaneous injection. The pharmacokinetic Tmax is 0.5–1.0 hours post subcutaneous injection. The approved product label specifies administration at least 45 minutes before anticipated sexual activity. Intranasal formulations studied in earlier phases showed slightly faster onset but were dropped due to bioavailability variance.
  • Plasma half-life of bremelanotide in human pharmacokinetic studies is approximately 2.5 hours (range 1.9–2.7 hours across studies). Tmax is approximately 1 hour post SC injection. Peak plasma concentration after 1.75 mg SC is approximately 72.8 ng/mL. Early intranasal Phase 1 studies reported half-life values of 1.85–2.09 hours.
  • Bremelanotide (the INN for PT-141) received FDA approval in June 2019 (NDA 210557) under the trade name Vyleesi for treatment of acquired, generalized HSDD in premenopausal women. The approved dose is 1.75 mg SC, maximum 1 dose per 24 hours, maximum 8 doses per month. PT-141 is not FDA-approved for erectile dysfunction, postmenopausal women, or any male indication.
  • The most common adverse events in Phase 3 bremelanotide trials were nausea (40.0% vs. 1.3% placebo), flushing (20.3% vs. 0.3%), and headache (11.3% vs. 1.9%). Transient systolic blood pressure increases of 3.1–3.2 mmHg were documented in ambulatory monitoring. Hyperpigmentation (face, gums, breast) was observed with consecutive daily research-protocol dosing.
  • PT-141 acts centrally on melanocortin receptors in the CNS to modulate desire and arousal initiation, while PDE-5 inhibitors act peripherally on vascular smooth muscle. Phase 2 studies show PT-141 produced responses in subjects who did not respond to sildenafil, demonstrating the central and peripheral pathways are independent. Unlike PDE-5 inhibitors, bremelanotide produces transient blood pressure increases (not decreases) — making it complementary rather than additive from a safety standpoint.
  • Bremelanotide as Vyleesi requires a prescription in the US. It is prescribed for HSDD in premenopausal women following clinical evaluation and diagnosis. PT-141 as a research chemical is handled under different regulatory frameworks. This site covers published research only and does not address sourcing, prescribing, or supply.
  • Research has focused on two areas: (1) sexual desire disorders in both sexes — particularly HSDD in premenopausal women (the approved indication) and erectile dysfunction in men (Phase 2 data) — and (2) central melanocortin MC4R signaling as a pharmacological target for CNS-mediated arousal. A secondary research area is the compound's pleiotropic effects on caloric intake and body weight at high-frequency dosing.
  • Research began with melanotan II and its incidental pro-erectile effects. Early directions included intranasal delivery, dose-finding in both sexes, and comparison with placebo and active controls. Neuroimaging work confirmed hypothalamic activation via c-Fos immunoreactivity in animals. The development program then split: HSDD trials in women (Phase 3, FDA approval achieved) and ED trials in men (Phase 2, not advanced to Phase 3).
  • In male trials, PT-141 produced pro-erectile effects via central pathway activation, measured by RigiScan monitoring and IIEF scores. In female trials (HSDD), the primary outcome was satisfying sexual events per month and FSDS-DAO distress reduction. Nausea rates were higher in women (~40% Phase 3) compared to adverse-event profiles in male Phase 2 studies. Animal models show the compound selectively increases appetitive (desire-initiation) behaviors in both sexes.
  • PT-141 does not operate via the hypothalamic-pituitary-gonadal axis and does not directly modulate testosterone production. It acts through MC3R/MC4R in the CNS. No significant testosterone elevation has been reported in clinical trial data. The compound's pleiotropic MC4R effects documented in clinical research relate to appetite and energy balance, not HPG-axis or gonadal steroid signaling.
  • PT-141 acts at MC1R at higher doses or higher dosing frequencies, which governs melanogenesis. Clinical trials and post-market data for bremelanotide document focal hyperpigmentation (face, gums, breast) as an adverse event. In research protocols using consecutive daily dosing for 16 days, over one-third of subjects developed hyperpigmentation. At label-compliant frequency (maximum 8 doses/month), hyperpigmentation was rare. Changes may persist after discontinuation.
  • Nausea was the most common adverse event in Phase 3 bremelanotide trials, reported in ~40% of subjects versus 1.3% placebo. It was the leading cause of discontinuation. The mechanism is consistent with MC4R agonism in emetic pathways. Co-administration of ondansetron and patient selection (avoiding subjects with nausea history) reduced discontinuation rates in the clinical program.
  • Phase 1–2 studies tested intranasal delivery. Phase 3 pivotal trials and the approved product use subcutaneous auto-injector (abdomen, thigh, or upper arm). The intranasal formulation was dropped due to bioavailability variance. Intravenous administration was studied in Phase 1 safety work only. The approved Vyleesi product uses exclusively subcutaneous delivery.
  • PT-141 is a non-selective melanocortin receptor agonist with primary activity at MC3R and MC4R, concentrated in the hypothalamus and limbic system. MC4R activation in the mPOA is believed responsible for the pro-sexual effects. MC3R's role is less characterized. MC1R is activated at higher doses, accounting for the hyperpigmentation adverse event via melanogenesis. A 2023 mouse study confirmed MC4R signaling in Sim1 hypothalamic neurons is sufficient for sexual receptivity.
  • The Phase 3 RECONNECT trials (NCT02333071, NCT02338960) demonstrated statistically significant increases in satisfying sexual events per month and reductions in FSDS-DAO distress scores versus placebo in premenopausal women with HSDD. Response rates were approximately 58% bremelanotide vs. 36% placebo. Efficacy was consistent across demographic subgroups. These findings formed the basis of FDA approval for bremelanotide.
  • PT-141 remains one of the few centrally-acting compounds studied for male sexual desire. Phase 2 data in men with ED showed pro-erectile and pro-desire effects in a dose-dependent manner, including in subjects refractory to PDE-5 inhibitors. No Phase 3 program in men has been completed. The landscape of central-pathway male sexual-desire pharmacology is substantially less developed than the HSDD pipeline.
  • The clinical trial safety database includes ~3,500 subjects across 43 trials. Major concerns: nausea (~40%), transient blood pressure elevation (contraindication in uncontrolled hypertension), and hyperpigmentation at high-frequency dosing. The approved product carries a cardiovascular risk warning. At label-compliant frequency, the 52-week extension data showed no new safety signals through 76 weeks total exposure. No deaths were reported in the clinical program.
  • The approved bremelanotide regimen specifies no more than one dose per 24 hours and a maximum of 8 doses per month. Research protocols varied; chronic high-frequency daily dosing for 16 days was associated with hyperpigmentation in over one-third of subjects. The 52-week open-label extension and the Phase 3 data at label-compliant frequency represent the best available chronic-use safety evidence.